Search

Nick Kroll, Seth Meyers, Amy Schumer, John Mulaney, and special guests hosted the one-night-only event, taking the stage to outwit blood cancers and raising a record-breaking $2.3 million to fuel Memorial Sloan Kettering Cancer Center’s mission of ending cancer for life.

… Tuesday, May 20, 2025 Comedy vs Cancer, the official comedy benefit show for blood cancer research at Memorial Sloan Kettering Cancer Center (MSK), returned to Jazz at Lincoln Center’s Frederick P. Rose Hall. The sold-out, one-night-only event raised over $2.3   million to support lifesaving blood cancer

The FDA has approved the drug trastuzumab deruxtecan for the treatment of advanced non-small cell lung cancer driven by mutant HER2. An MSK-led study published in September 2021 contributed to the drug's approval.

… Friday, August 12, 2022 On August 11, 2022, the U.S. Food and Drug Administration (FDA) approved the drug trastuzumab deruxtecan (also known as T-DXd or Enhertu®) for the treatment of advanced non-small cell lung cancer (NSCLC) driven by mutant HER2. Trastuzumab deruxtecan was previously approved for

Daniela Molena, MD, Director, Esophageal Surgery Program, talks on expanding organ preservation surgery in esophageal cancer and the quest to pinpoint the elusive sentinel node in these patients.

… Wednesday, March 6, 2019 VIDEO | 03:47 Expanding Organ Preservation Surgery in Esophageal Cancer Daniela Molena, MD, Director, Esophageal Surgery Program, talks on expanding organ preservation surgery in esophageal cancer and the quest to pinpoint the elusive sentinel node in these patients. Video Details

At the 2016 American Association for Cancer Research (AACR) conference, there were clear signs that cancer treatment is evolving from a slash-and-burn method to a more precisely targeted, intelligent approach.

… Wednesday, April 20, 2016 Summary Genomic sequencing of tumors is allowing cancer researchers to tailor treatments to patients in a way that was previously not possible, allowing a more targeted, personalized approach to cancer care. Increasingly, the focus of research is on finding the right combination

Get to know Marissa Gredler, a postdoctoral fellow in the Sloan Kettering Institute.

… Friday, March 27, 2020 Summary As part of Women’s History Month, we are profiling some of MSK’s star female graduate students and postdoctoral fellows training to be leaders in their fields. Marissa Gredler is a postdoctoral fellow in the Zallen lab  in the Sloan Kettering Institute. When and how did

An MSK study found a rise in lumpectomies and a decline in mastectomies — reversing a trend that experts say was leading to the overtreatment of breast cancer.

… Wednesday, July 13, 2022 When Kate Delp was diagnosed with stage 2 breast cancer , she faced a decision: Should she have a lumpectomy or a mastectomy ? “From what I’d heard about mastectomy, I knew that it was a very invasive surgery and difficult to go through,” says Kate, who lives in New Jersey and

A team of scientists at the Sloan Kettering Institute has identified the STING cellular signaling pathway as a key player in keeping dormant cancer cells from progressing into aggressive tumors months, or even years, after they’ve escaped from a primary tumor.

… Wednesday, March 29, 2023 Highlights MSK researchers identified a key role for the STING signaling pathway in preventing dormant metastatic cancer cells from progressing to active metastases. Treating laboratory mice with a STING activator helped eliminate lingering metastatic cells and stop the development

An innovative technique called stereotactic hypofractionated accelerated radiation to the prostate – aka SHARP - safely and effectively delivers powerful doses of radiation directly to the patient’s tumor with incredible precision.

… Friday, June 2, 2017 For decades, experts at Memorial Sloan Kettering have been pioneering sophisticated ways to safely and effectively deliver powerful doses of radiation directly to a person’s tumor with incredible precision. One recent example of these ongoing efforts is an innovative technique called

New MSK research showed giving chemotherapy shortly after a stem cell or bone marrow transplant from a less than perfectly matched donor greatly reduces the chances that the patient will develop graft-versus-host disease (GVHD); and sheds new light on cell state changes in prostate cancer.

… Wednesday, July 31, 2024 New research from Memorial Sloan Kettering Cancer Center (MSK) showed giving chemotherapy shortly after a stem cell or bone marrow transplant from a less than perfectly matched donor greatly reduces the chances that the patient will develop graft-versus-host disease (GVHD); and

Recent data from Memorial Sloan Kettering shows that a real-time breast ultrasound exam after second opinion review of outside, static breast ultrasound images led to a change in the initially prescribed management in 32.5 percent of included patients.

… Monday, October 16, 2017 Asymptomatic women who undergo routine breast cancer screening with imaging may be uncertain of the next steps when an unexpected suspicious finding or cancer is reported in the context of their annual visit with a primary care doctor in the community setting. For these women